Evidence map›Paper›PMID 42323405›Full record

ArticleCommunications biology2026

Insufficient ferroptosis in radiation-induced tumor cells promote Treg cell generation to induce radiotherapy resistance.

Yue Wu, Yanyang Zhu, Chang Yu, Yuchen Yu, Yi Luo, Yi Zhang, Yonglei Xiao, Qiuyu Zhang

Abstract read
In one paragraph

Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yue Wu *Institute of Immunotherapy, Fujian Medical University, Fuzhou, China.
Yanyang Zhu *Institute of Immunotherapy, Fujian Medical University, Fuzhou, China.
Chang YuInstitute of Immunotherapy, Fujian Medical University, Fuzhou, China.
Yuchen YuInstitute of Immunotherapy, Fujian Medical University, Fuzhou, China.
Yi LuoInstitute of Immunotherapy, Fujian Medical University, Fuzhou, China.
Yi ZhangInstitute of Immunotherapy, Fujian Medical University, Fuzhou, China.
Yonglei XiaoInstitute of Immunotherapy, Fujian Medical University, Fuzhou, China.
Qiuyu ZhangInstitute of Immunotherapy, Fujian Medical University, Fuzhou, China. qiuyu.zhang@fjmu.edu.cn.ORCID http://orcid.org/0000-0003-4081-7480

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82073350
6 · The paper itself

Abstract

Recently, cellular mechanisms underlying radioresistance in the tumor microenvironment (TME) attract increasing attention, but how the resistant tumor cells reshape the TME is still unclear. In this study, we find that the ferroptosis-resistant genes are upregulated in radioresistant tumor cells, resulting in the impairment of radiation-induced ferroptosis in radioresistant cells. Additionally, the release of transforming growth factor beta 1 (TGF-β1) is increased in radioresistant tumor cells, contributing to Treg cell infiltration in radioresistant tumor tissues. Hence, the ferroptosis inducer sorafenib enhances the sensitivity of local irradiation in radioresistant tumor models by inhibiting Treg cell infiltration. Furthermore, database analysis of The Cancer Genome Atlas shows that the score of ferroptosis-resistant genes positively correlates with both TGF-β1 expression level and Treg cell infiltration score in several types of tumor tissues. The ferroptosis-resistance score of TME is higher in non-responders than in responders of colorectal cancer and breast cancer. These findings suggest irradiation-induced insufficient ferroptosis promotes the accumulation of Treg cells via the release of TGF-β1, providing new insights for clinical trials designing the combination of ferroptosis-inducing chemotherapy with radiotherapy to overcome radioresistance.

Indexed as

FerroptosisNeoplasmsRadiation ToleranceT-Lymphocytes, RegulatoryAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMiceSorafenibTransforming Growth Factor beta1Tumor MicroenvironmentSorafenibTransforming Growth Factor beta1

Identifiers

PMID42323405
PMCPMC13642955

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.